Edition:
India

Myriad Genetics Inc (MYGN.OQ)

MYGN.OQ on NASDAQ Stock Exchange Global Select Market

29.13USD
23 Apr 2018
Change (% chg)

$0.23 (+0.80%)
Prev Close
$28.90
Open
$28.87
Day's High
$29.33
Day's Low
$28.86
Volume
231,760
Avg. Vol
298,811
52-wk High
$41.52
52-wk Low
$17.73

Select another date:

Mon, Apr 2 2018

BRIEF-Myriad Receives Pre Market Approval For Its Bracanalysis Diagnostic System In Japan

April 2 Myriad Genetics Inc - ‍Astrazeneca And Merck Are Seeking Approval Of Lynparza In Japan For Treating Patients With Brca :

BRIEF-Myriad Genetics Q2 Adjusted Earnings Per Share $0.31

* MYRIAD GENETICS REPORTS FISCAL SECOND-QUARTER 2018 FINANCIAL RESULTS

UPDATE 1-U.S. FDA approves expanded use of AstraZeneca cancer drug

Jan 12 The U.S. Food and Drug Administration said on Friday it has approved expanded use of AstraZeneca Plc's cancer drug Lynparza to include patients with metastatic breast cancer whose disease is associated with a mutation of the BRCA gene.

BRIEF-Myriad Genetics posts Q1 adjusted earnings per share $0.26

* Myriad Genetics reports fiscal first-quarter 2018 financial results

BRIEF-Myriad announces GeneSight Psychotropic results from a large prospective trial in patients with major depressive disorder

* Myriad announces GeneSight® Psychotropic results from a large prospective trial in patients with major depressive disorder

BRIEF-‍Myriad Genetics announces new positive results for EndoPredict

* Endopredict (epclin) shown in second study to be more effective than oncotype dx® (rs) in women with intermediate risk of breast cancer recurrence

BRIEF-Myriad submits BRACAnalysis® CDx application for regulatory approval in Japan

* Myriad submits BRACAnalysis® CDX application for regulatory approval in Japan for HER2- metastatic breast cancer

Select another date: